Johnson & Johnson CDR (CAD Hedged)

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval for Gobivaz, Alvotech's proposed biosimilar to Simponi.

Johnson & Johnson's Phase 2 MajesTEC-5 study demonstrates that 100% of evaluable patients achieved minimal residual disease negativity following TECVAYLI and DARZALEX FASPRO-based induction therapy.

Shanghai Henlius Biotech is negotiating with pharmaceutical giants Johnson & Johnson and Roche to sell rights to an experimental cancer drug.

Odyssey Therapeutics closed an oversubscribed $213 million Series D financing round to accelerate development of its autoimmune and inflammatory disease treatments after abandoning IPO plans in June.

Dr. Reddy's Laboratories has acquired the STUGERON brand from Johnson & Johnson for $50.5 million, expanding its central nervous system therapeutic portfolio across 18 markets in Asia-Pacific and EMEA regions.

Ronovo Surgical closed a $67 million Series D funding round led by Johnson & Johnson Development Corporation, bringing the company's 2025 fundraising total to over $100 million.

The combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) achieved 61% three-year survival versus 53% with osimertinib in first-line EGFR-mutated NSCLC treatment.

Johnson & Johnson's Impella CP heart pump showed a 16.3% absolute mortality reduction at 10 years compared to standard care in patients with cardiogenic shock following heart attack.

Predicine has submitted the first module of a premarket approval application to the FDA for PredicineCARE, a urine cell-free DNA next-generation sequencing assay for use as a companion diagnostic in bladder cancer.

Johnson & Johnson discontinued its Phase 2 DAISY trial of nipocalimab combined with anti-TNFα therapy for rheumatoid arthritis after failing to demonstrate sufficient added benefit over monotherapy at 12 weeks.